DarshanTalks Podcast – Détails, épisodes et analyse

Send us Fan Mail

 A lot of brands start with harmless wellness promises like better mood, more energy, or improved sleep. As the business grows, though, marketing often becomes bolder, and that’s where risk creeps in. The FDA steps in when your claims imply treating or preventing a disease, which can flip your product into drug or device territory. The FTC expects every wellness claim to be truthful and supported by real evidence. In this episode, I explain how I review labels, websites, and social content, map each claim to the right regulatory bucket, and draft compliant alternatives that keep your marketing appealing without triggering expensive oversight. I also build claim checklists to help teams avoid drift in the future. Call, click, or email if you need support. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

 A knee implant meant to restore mobility. A surgeon secretly collecting international trips and consulting checks. A device company accused of selling a product they allegedly knew would fail. This episode breaks down the Aesculap case, the $38.5M settlement, and what it teaches us about kickbacks, forged FDA documents, and the catastrophic cost of weak compliance controls. If your team works in pharma, med-tech, or clinical research, you don’t want to miss this one. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this episode, host Darshan Kulkarni speaks with Joseph Keeney about speaker programs in the life sciences industry, exploring practical differences between small and large companies. They highlight that while fundamentals like compliance, pragmatism, and sound business principles apply across organizations, strong mitigating controls and adherence to legal and industry codes are critical.

Joseph explains the importance of engaging with various business units to understand real plans, aligning training programs with compliance needs, and avoiding pitfalls that could trigger violations of federal anti-kickback statutes. He emphasizes careful management of speakers bureau rosters, evaluating the necessity and effectiveness of healthcare professionals (HCPs) on the program, and considering fair market value while avoiding indirect remuneration risks.

The conversation also covers compensation approaches, proper documentation, and the value of third-party partners for benchmarking and compliance review. Joseph stresses that each program should be tailored to the company’s unique needs and highlights the importance of ongoing evaluation, diligence, and oversight.

Reach out to learn more. 

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this episode, Darshan Kulkarni sits down with Raymond Nomizu, founder and co-CEO of CRIO, to discuss key takeaways from the SOS conference and the evolving landscape of clinical research.

Raymond shares his journey from running a clinical research site to founding CRIO, a platform designed to modernize site operations through eSource, CTMS, and real-time data solutions. They explore major industry trends, including the rise of site networks, increasing sponsor demand for real-time data access, and the shifting role of decentralized clinical trials (DCTs).

They also discuss whether DCTs are truly revolutionizing research or simply becoming part of standard clinical operations. Raymond emphasizes that while centralization can improve efficiency in areas like finance, data management, and regulatory processes, the investigator-patient relationship must remain localized for research to be effective.

The SOS conference highlighted these ongoing shifts, and the conversation dives into how sites can stay competitive by adapting to sponsor expectations, leveraging technology, and optimizing operations.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Darshan talks about a major blind spot in food M&A—hidden compliance risks that can destroy a deal overnight. While most focus on financials, market share, and synergies, they fail to account for regulatory pitfalls that can trigger investigations, recalls, or severe penalties. Imagine being deep in negotiations, only to discover unapproved ingredients, misleading health claims, or an undisclosed FDA warning letter buried in company files. Some executives make the mistake of pushing forward, thinking they’ll fix it later—but regulators like the FDA, USDA, and FTC won’t wait.

Many assume their internal legal teams can handle compliance due diligence, but food regulations are complex, spanning labeling, safety, advertising, and state consumer protection laws. The Kulkarni Law Firm specializes in identifying and resolving these risks before they become deal-breakers. We help buyers conduct regulatory due diligence, engage with federal and state regulators, assess liability risks in labeling and advertising, and structure compliance-driven transactions.

If you're involved in food M&A, don’t let compliance issues turn your investment into a liability. Reach out to the Kulkarni Law Firm to protect your deal and ensure regulatory success.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The recent $47 million settlement involving QOL Medical and its CEO is a stark reminder of the consequences of crossing legal and ethical boundaries. Allegations of offering free Carbon 13 breath test kits as kickbacks to induce prescriptions for Sucraid, a treatment for congenital sucrose isomaltase deficiency (CSID), aren't just about non-compliance—they’re about patient safety. The breath tests could not specifically diagnose CSID but were marketed as such, leading to inappropriate prescriptions and fraudulent claims submitted to federal healthcare programs. This not only wasted resources but also put vulnerable patients at risk.

For those in the rare disease treatment space, this case highlights the need for transparency and truth in marketing. Ask yourself: Are your promotional strategies truthful? Are you offering incentives that could be misconstrued as kickbacks? In a field with limited data and high stakes, misleading marketing can erode trust, tarnish reputations, and invite legal scrutiny. Compliance is not just a checkbox—it’s a commitment to ethical practices that prioritize patient well-being. As you navigate these challenges, ensure your marketing practices are compliant while effectively educating healthcare providers about rare disease treatments. QOL Medical’s costly misstep should serve as a warning. 

For guidance on staying compliant, reach out to the Kulkarni Law Firm and learn how we can help.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Edye Edens from KLF offers a brief yet in-depth overview of FDA regulatory submissions for clinical research in the U.S., reflecting on both current practices and predictions for 2025. She highlights how AI tools and evolving political dynamics are shaping the regulatory landscape, emphasizing that while efficiency improvements are necessary, careful and strategic approaches are critical to maintain the FDA’s global reputation and safety standards.

Edye discusses the complexity of submissions like Investigational New Drug (IND) and Investigational Device Exemption (IDE) applications, noting the significant preclinical work, detailed documentation, and thorough FDA review process involved. She also underscores the global weight of FDA approvals, as many international regulatory bodies rely on FDA assessments as a benchmark.

Finally, Edye poses key questions to her audience:

• How familiar are you with regulatory submissions?
• Are you considering outsourcing this complicated process?
• Where do you see opportunities for efficiency—through AI, technology, or administrative changes?
• If you’ve been a reviewer, how do you balance efficiency with safety?

Reach out for more info!

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

Carly Schaechter  discusses the potential of VR in drug promotion and the challenges of reviewing VR content for the PRC. Key points include the need for VR expertise to conceptualize interactive, engaging content. Choosing VR over AR depends on the objectives, with VR offering more controlled environments. Ensuring user control, addressing misinformation, and learning from past mistakes are crucial for successful VR implementation. Gamification and user experience evaluation are critical elements of the review process.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

In this insightful discussion, Shuja Naqvi, CEO of Biopharma Informatics, joins Darshan Kulkarni to explore the evolving landscape of clinical research. Shuja shares how his company has expanded across seven states, strategically choosing locations to promote diversity—not just in ethnicity, but also in socioeconomic and regional representation. He highlights the importance of gathering data from various populations to improve the effectiveness and inclusivity of clinical trials.

They delve into the growing role of research as a care option, particularly for uninsured patients who, through clinical trial participation, gain access to free medical care, medications, and life-saving screenings. While this model presents clear benefits, it also raises ethical concerns, such as the potential for undue influence when patients rely on trials for necessary healthcare. Shuja emphasizes the role of informed consent and IRB oversight in ensuring that participation remains voluntary and ethical.

The conversation also addresses compensation for trial participants. Shuja argues that current payments are insufficient, considering the risks involved in testing non-FDA-approved treatments. He stresses that researchers should ask themselves: “Would I enroll my own family in this trial?” If not, it’s a sign that ethical standards and participant compensation need to be reconsidered.

Support the show

www.kulkarnilawfirm.com

Send us Fan Mail

The EMA's new guiding principles on LLMs represent a transformative step in regulatory science, addressing both the immense potential and significant risks of these technologies. These principles emphasize the need to balance innovation with ethical considerations, tackling issues like data privacy, misinformation, and bias. LLMs, such as ChatGPT, hold promise for automating workflows like medical translations, pharmacovigilance reporting, and coding support. However, the EMA stresses continuous education, ethical governance, and collaboration among stakeholders to ensure responsible use.

Key recommendations include adopting strategies like prompt engineering to optimize AI outputs and fostering collaboration through initiatives like the European Specialized Expert Community (ESEC) for AI knowledge sharing. Bite-sized, accessible training programs can also help demystify LLMs for teams. As the life sciences sector embraces these tools, organizations must align with these principles to ensure compliant and impactful AI integrations. The Kulkarni Law Firm offers expert advice for ethical AI deployment—don’t wait to make your AI strategy future-ready!

Support the show

www.kulkarnilawfirm.com